期刊
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
卷 1865, 期 9, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.bbalip.2020.158756
关键词
LTB4; Lipid mediators; BLT1; BLT2; Eye; Age related macular degeneration; Allergic conjunctivitis
资金
- MEXT/JSPS KAKENHI [19K23851, 20K18395, 19K09980, 15H05904, 15H04708, 18H02627]
- Naito Foundation
- Ono Medical Research Foundation
- Uehara Memorial Foundation
- Mitsubishi Foundation
- Takeda Science Foundation
- Foundation of Strategic Research Projects in Private Universities from the MEXT [S1311011]
- Grants-in-Aid for Scientific Research [19K23851, 20K18395, 19K09980] Funding Source: KAKEN
Leukotriene B-4 (LTB4) is an inflammatory lipid mediator produced from arachidonic acid by multiple reactions catalyzed by two enzymes 5-lipoxygenase (5-LOX) and LTA(4) hydrolase (LTA(4)H). The two receptors for LTB4 have been identified: a high-affinity receptor, BLT1, and a low-affinity receptor, BLT2. Our group identified 12(S)-hydroxy-5Z,8E,10E-heptadecatrienoic acid (12-HHT) as a high-affinity BLT2 ligand. Numerous studies have revealed critical roles for LTB4 and its receptors in various systemic diseases. Recently, we also reported the roles of LTB4, BLT1 and BLT2 in the murine ophthalmic disease models of mice including cornea wound, allergic conjunctivitis, and age-related macular degeneration. Moreover, other groups revealed the evidence of the ocular function of LTB4. In the present review, we introduce the roles of LTB4 and its receptors both in ophthalmic diseases and systemic inflammatory diseases. LTB4 and its receptors are putative novel therapeutic targets for systemic and ophthalmic diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据